^
Association details:
| Biomarker: | NFATC1 overexpression |
|---|---|
| Cancer: | Pancreatic Cancer |
| Drug: | Flynpovi (eflornithine/sulindac) (Ornithine decarboxylase inhibitor, COX inhibitor, SSAT activator) |
| Direction: | Resistant |
Evidence:
Source:
Title:
Phospho-sulindac inhibits pancreatic cancer growth: NFATc1 as a drug resistance candidate
Excerpt:
...over-expressing the NFATc1 gene made the pancreatic cancer cells less responsive to treatment with P-S. NFATc1 likely mediates drug resistance to P-S and is an unfavorable prognostic factor that predicts poor tumor response.
DOI:
10.3892/ijo.2013.2190
